Search bioRxiv⌕ Search

bioRxiv · 10.1101/2024.08.13.607617

Silver nanoparticle induced immunogenic cell death can improve immunotherapy

Abstract

Cancer immunotherapy is often hindered by an immunosuppressive tumor microenvironment (TME). Various strategies are being evaluated to shift the TME from an immunologically cold to hot tumor and hereby improve current immune checkpoint blockades (ICB). One particular hot topic is the use of combination therapies. Here, we set out to screen a variety of metallic nanoparticles and explored their in-vitro toxicity against a series of tumor and non-tumor cell lines. For silver nanoparticles, we also explored the effects of core size and surface chemistry on cytotoxicity. Ag-citrate-5nm nanoparticles were found to induce high cytotoxicity in Renca cells through excessive generation of reactive oxygen species (ROS) and significantly increased cytokine production. The induced toxicity resulted in a shift of the immunogenic cell death (ICD) marker calreticulin to the cell surface in-vitro and in-vivo. Subcutaneous Renca tumors were treated with anti-PD1 or in combination with Ag-citrate-5nm. The combination group resulted in significant reduction in tumor size, increased necrosis, and immune cell infiltration at the tumor site. Inhibition of cytotoxic CD8+ T cells confirmed the involvement of these cells in the observed therapeutic effects. Our results suggest that Ag-citrate-5nm is able to promote immune cell influx and increase tumor responsiveness to ICB therapies.

Source connections

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Sargsian, A., Koutsoumpou, X., Girmatsion, H., Buttiens, K., Rios Luci, C., Soenen, S. J., Manshian, B. B.. 2024-08-16. Silver nanoparticle induced immunogenic cell death can improve immunotherapy. https://doi.org/10.1101/2024.08.13.607617

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Rac1 and CHK1 Converge on Abi-1 to Regulate DNA Repair Dependency and Treatment Response in Human Cancers

Radiation therapy (RT) resistance remains a major clinical challenge, yet biomarkers guiding precision radiosensitization are lacking. We previously demonstrated that Rac1 promotes RT resistance in glioblastoma (GBM) by inducing Abi-1-S323 dephosphorylation and enhancing non-homologous end joining (NHEJ). Here, we identify Abi-1-S323 as a key regulator of DNA repair states and a determinant of therapeutic efficacy in human cancers. Clinically, loss of Abi-1-S323 phosphorylation was associated with poor outcomes in patients with RT-treated GBM. Bioinformatic analyses revealed that non-small cell lung cancer (NSCLC) and head and neck cancer (HNC) are among the cancers with frequent RAC1 amplification, suggesting that these tumor types may have increased Rac1-Abi-1 signaling activity. Loss of Abi-1-S323 phosphorylation also predicted poor outcomes in patients with RT-treated HNC. Consistent with these clinical observations, high Rac1 activity and low Abi-1-S323 phosphorylation were associated with enhanced DNA double-strand break repair and radioresistance in NSCLC and HNC models, whereas genetic or pharmacological inhibition of this signaling impaired DNA repair and radiosensitized tumors in vitro and in vivo. Mechanistically, we identified CHK1 as a kinase that phosphorylates Abi-1 at S323 and defines an alternative homologous recombination (HR)-dependent repair state. Tumors with high Rac1-Abi-1 signaling exhibited elevated NHEJ capacity and were selectively radiosensitized by Rac1 inhibition, whereas tumors with low Rac1-Abi-1 signaling displayed high CHK1 activity, preferentially relied on HR, and were selectively radiosensitized by CHK1 inhibition. These findings establish Abi-1-S323 as a biomarker defining therapeutically distinct DNA repair states and provide a framework for precision radiosensitization.

cancer biology↗

Vulnerability of triple negative breast cancer to daraxonrasib pan-RAS(on) inhibition

Triple-Negative Breast Cancer (TNBC) is a clinical subtype where aberrant expression of receptor tyrosine kinases (RTKs) leads to the activation of the RAS-RAF-MEK-ERK pathway contributing to tumor progression. Therapies targeting components of the RAF-MEK-ERK pathway in TNBC have been disappointing due to rapid onset of adaptive reprogramming of the RTK landscape leading to pathway reactivation. To overcome the dynamic heterogeneity of RTK expression and their convergence in activating RAS, treatment with the pan-RAS(on) inhibitor daraxonrasib (RMC-6236), which inhibits RAS-GTP regulation of RAF kinases, inhibited proliferation independent of TNBC kinotype or oncogenic RAS mutation in three of four TNBC cell lines in vitro and two patient-derived TNBC xenografts in mice. Daraxonrasib in combination with the MEK inhibitor trametinib prevented reactivation of the RAF-MEK-ERK pathway observed with each inhibitor alone and further enhanced inhibition of tumor growth in TNBC cell lines and xenografts. Inhibiting pan-RAS(on) RAS-GTP, with daraxonrasib, alone or in combination with a MEK inhibitor, provides a new strategy for the treatment of TNBC that inhibits RTK activation of the RAS-RAF-MEK-ERK pathway and tumor proliferation.

cancer biology↗

Resource limitation rewires chromosome instability and ploidy evolution across in vitro and in vivo cancer models

Whole-genome doubling (WGD) and elevated ploidy are pervasive features of cancer that shape chromosomal instability (CIN), therapeutic response, and metastatic fitness. Yet ploidy is strikingly context dependent: many tumors remain near diploid in vivo despite the frequent emergence of highly polyploid states in vitro. Here, we estimate ploidy dependent chromosome missegregation tolerance using a mathematical model calibrated to growth and chromosome number data from matched near diploid and near tetraploid breast cancer cultures and xenografts. The model architecture reflects a tug of war between two opposing selective forces acting on ploidy--resource limitation that caps high ploidy by imposing energetic and biosynthetic costs, and CIN that can favor higher ploidy by buffering the fitness impact of chromosome gains and losses. The fitted model reproduced chromosome losses in 4N cultures and WGD followed by chromosome losses in 2N cultures. In vivo, the strongest determinants of ploidy shifted from stress associated death at low oxygen to baseline missegregation at higher oxygen. Joint calibration to both in vivo and in vitro contexts assigned tumors lower proliferation, an approximately tenfold higher stress-associated death scale, and an 11-16 fold larger maximal stress induced missegregation increment than cultures. Simulating populations across combinations of constant oxygen levels and missegregation settings showed that ploidy increased with oxygen under conditions supporting population growth. In both culture and tumors, mean ploidy above tetraploidy was associated with population decline. Together, the framework predicts when resource constraints favor chromosome loss and when missegregation tolerance permits high ploidy expansion, providing testable expectations for how CIN perturbations reshape ploidy evolution in different resource environments.

cancer biology↗